{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:08Z","timestamp":1787013908880,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To evaluate the long\u2010term efficacy, safety, and tolerability of aripiprazole in pediatric subjects with bipolar I disorder.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    A randomized, double\u2010blind, 30\u2010week, placebo\u2010controlled study of aripiprazole (10 or 30\u2003mg\/day) in youths (10\u201317\u2003years) with bipolar I disorder (manic or mixed) \u00b1 psychotic features (n\u2003=\u2003296) was performed. After four weeks, acute treatment completers continued receiving \u226426\u2003weeks of double\u2010blind treatment (n\u2003=\u2003210). The primary outcome was Young Mania Rating Scale (YMRS) total score change.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Of the 210 subjects who entered the 26\u2010week extension phase, 32.4% completed the study (45.3% for aripiprazole 10\u2003mg\/day, 31.0% for aripiprazole 30\u2003mg\/day, and 18.8% for placebo). Both aripiprazole doses demonstrated significantly (p\u2003&lt;\u20030.001) greater improvements in YMRS total score at endpoint compared with placebo in protocol\u2010specified last observation carried forward analyses, but not in observed case or mixed\u2010model repeated measures at week 30. Overall time to all\u2010cause discontinuation was longer for aripiprazole 10\u2003mg\/day (15.6\u2003weeks) and aripiprazole 30\u2003mg\/day (9.5\u2003weeks) compared with placebo (5.3\u2003weeks; both p\u2003\n                    <jats:italic>&lt;<\/jats:italic>\n                    \u20030.05 versus placebo). Both aripiprazole doses were significantly superior to placebo regarding response rates, Children\u2019s Global Assessment of Functioning and Clinical Global Impressions\u2010Bipolar severity of overall and mania scores at endpoint in all analyses. Commonly reported adverse events included headache, somnolence, and extrapyramidal disorder.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    Aripiprazole 10\u2003mg\/day and 30\u2003mg\/day were superior to placebo and generally well tolerated in pediatric subjects with bipolar I disorder up to 30\u2003weeks. Despite the benefits of treatment, completion rates were low in all treatment arms.\n                  <\/jats:p>","DOI":"10.1111\/bdi.12042","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T10:56:42Z","timestamp":1361789802000},"page":"138-149","source":"Crossref","is-referenced-by-count":83,"title":["Aripiprazole for the treatment of pediatric bipolar I disorder: a 30\u2010week, randomized, placebo\u2010controlled study"],"prefix":"10.1111","volume":"15","author":[{"given":"Robert L","family":"Findling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretta","family":"Nyilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Mankoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle A","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579406060500"},{"key":"e_1_2_7_3_2","unstructured":"DelbelloMP FindlingRL EarleyWRet\u00a0al.Efficacy of quetiapine in children and adolescents with bipolar mania: a 3\u2010week double\u2010blind randomized placebo\u2010controlled trial. Poster presented at the 46th Annual Meeting of the American College of Neuropsychopharmacology December 9\u201313 2007 Boca Raton FL USA."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00750.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05164yel"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07104"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0621-y"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.10.025"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1003"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0414"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106059693"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.40102.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.13.2.267"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022620217886"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000198590.38325.81"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_7_25_2","first-page":"534","volume-title":"Abnormal Involuntary Movement Scale (AIMS)","author":"Guy W","year":"1976"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/104454603321666216"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.05.017"},{"key":"e_1_2_7_28_2","unstructured":"FindlingR DelbelloM WangPet\u00a0al.Long\u2010term safety and tolerability of ziprasidone in children and adolescents with bipolar disorder. Poster presented at the 55th Annual Meeting of American Academy of Child and Adolescent Psychiatry October 28 to November 2 2007 Chicago IL USA."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.12.1305"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.019"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000194567.63289.97"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595568"},{"issue":"4","key":"e_1_2_7_33_2","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll CU","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"e_1_2_7_34_2","first-page":"1","article-title":"Second\u2010generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"e_1_2_7_35_2","first-page":"596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","volume":"27","author":"ADA\/APA\/AACE\/NAASO","year":"2004","journal-title":"Diabetes Care"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(98)00049-2"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbdi.12042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bdi.12042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:17:48Z","timestamp":1698635868000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bdi.12042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,25]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/bdi.12042"],"URL":"https:\/\/doi.org\/10.1111\/bdi.12042","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,25]]}}}